Doravirine (DOR) efficacy and safety have been evaluated in adult naive or treated patients starting a DOR-based regimen between September 15, 2019, and December 31, 2020. Medical history and examination, laboratory results, and tolerance were assessed during the 48 weeks of follow-up. Among the 77 patients included, virological control (VC) was noticed for 66 patients at baseline. Median age was 51 years, and 62% were men. The most common reason for initiating a DOR-based therapy was toxicity (44; 67%) and, especially, weight gain. A virological suppression (VS) was maintained in 55 (83%) patients of the VC group and noticed in 9 (82%) of the non-VC patients at week 48, by intention-to-treat analysis. On treatment analysis, 98% and 100% patients achieved VS in the VC and non-VC groups, respectively. The renal and metabolic tolerance were good. DOR-based regimens appear to be a safe and relevant strategy to circumvent drug interactions and drugs with a poor metabolic tolerance profile.

中文翻译：

---

基于 Doravirine 的方案在现实生活中的有效性和安全性：一项前瞻性单中心法国研究

已在 2019 年 9 月 15 日至 2020 年 12 月 31 日期间开始基于 DOR 方案的成人初治或治疗患者中评估了 Doravirine (DOR) 的疗效和安全性。在 48 周期间评估了病史和检查、实验室结果和耐受性的后续行动。在包括的 77 名患者中，66 名患者在基线时注意到病毒学控制 (VC)。中位年龄为 51 岁，62% 为男性。开始基于 DOR 的治疗的最常见原因是毒性（44；67%），尤其是体重增加。通过意向治疗分析，在第 48 周时，VC 组的 55 名 (83%) 患者保持病毒学抑制 (VS)，并注意到 9 名 (82%) 的非 VC 患者。在治疗分析中，VC 组和非 VC 组分别有 98% 和 100% 的患者实现了 VS。肾脏和代谢耐受性良好。